Answers are grounded in this paper and cite their sources.
There is an urgent need for oral agents to combat resistant Gram-negative pathogens. Here, we describe the characterization of VNRX-5236, a broad-spectrum boronic acid β-lactamase inhibitor (BLI), and its orally bioavailable etzadroxil prodrug, VNRX-7145.
No takes yet. Share an insight, caveat, or question.
Chatwin et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: